

Highly Specialised Technology Committee Interests Register

Topic: Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Elizabeth Toy	Clinical Expert	Indirect - financial	<p>Attendance at ESMO 2023 (including conference fees, travel and accommodation) where a number of trials and investigational products relating to lung cancer were presented was sponsored by MSD - Value unknown.</p> <p>Elizabeth has given invited talks to AstraZeneca on the subject of lung cancer pathways and has received honoraria for attendance at advisory boards in relation to integration of their products in lung cancer management pathways</p> <p>Elizabeth has taken part in advisory boards regarding Selpercatanib, another small molecule therapy, for Lilly Oncology, however this is not relevant to this appraisal</p>	24/11/2024 20/11/2025	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal
Professor Alistair Greystoke	Clinical Expert	Direct – financial	Alistair declared the following interest: Previous advisory board and speaker fees from AstraZeneca: none related to this appraisal.	19/06/2025 20/11/2025	It was agreed that Alistair's' declaration would not prevent them from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Emtiyaz Chowdhury	HST Committee Member	Non-financial Professional	Emtiyaz is employed by Parexel. Parexel offers services to Immedica. I've not been directly involved with any work related to this technology.	19/06/2025 20/11/2025	It was agreed that Emtiyaz's declaration would not prevent them from participating in discussions on this evaluation.
Stuart Mealing	HST Committee Member	Non-financial Professional	Stuart is currently working on a manuscript for a new asthma care pathway with a group of researchers from University of Hull based on a trial that was funded by AstraZeneca and the manuscript has AZ authors on it.	19/06/2025 20/11/2025	It was agreed that Stuart's declaration would not prevent them from participating in discussions on this evaluation.
Natalia Kunst	HST Committee Member	Non-financial Professional	Natalia is employed by BMS who have a drug for the same indication.	19/06/2025 20/11/2025	It was agreed that Natalia's declaration would prevent them from participating in discussions on this evaluation.